Search

Displaying results 5271 - 5280 of 8974 in total
  1. Drug

    DL-alpha-Tocopherol

    go.drugbank.com/drugs/DB14476
    ApprovedInvestigational

    Mixtures: CERNEVIT FOR INJECTION
  2. Drug

    Rolofylline

    go.drugbank.com/drugs/DB12670
    Investigational

    Rolofylline is under clinical development by pharmaceutical company NovaCardia for the treatment of congestive heart failure.

  3. Drug

    Adlinacogene civaparvovec

    go.drugbank.com/drugs/DB16788
    Investigational

    [L46711] Developed by Sangamo Therapeutics Inc., it is being investigated for the treatment of hemophilia B.[L46706] … It uses proprietary zinc finger nuclease (ZFN) genome editing to insert into the DNA of liver cells a copy of the F9 gene, which controls the production of Factor IX.

  4. Drug

    Phencyclidine

    go.drugbank.com/drugs/DB03575
    ExperimentalIllicit

    A hallucinogen formerly used as a veterinary anesthetic, and briefly as a general anesthetic for humans. Phencyclidine is similar to ketamine in structure and in many of its effects.

  5. Drug

    Diacetyl benzoyl lathyrol

    go.drugbank.com/drugs/DB11260
    Approved

    It is also reported to be a skin conditioning agent.

    Mixtures: O HUI white-skin science white calming mask
  6. Drug

    HSV-2 theracine

    go.drugbank.com/drugs/DB05811
    Experimental

    HSV-2 theracine is an attenuated recombinant vaccine developed by AuRx for the treatment of genital herpes.

  7. Drug

    Oxyphencyclimine

    go.drugbank.com/drugs/DB00383
    Approved

    Oxyphencyclimine is an anticholinergic drug (trade name Daricon) used in treating peptic ulcers.

    Categories: Drugs for Functional Gastrointestinal Disorders
  8. Drug

    Vicriviroc

    go.drugbank.com/drugs/DB06652
    Investigational

    Vicriviroc, also known as SCH 417690 and SCH-D, is currently in clinical trials for the management of HIV-1. … This drug was developed by Schering-Plough.

  9. Drug

    AZD0947

    go.drugbank.com/drugs/DB04848
    Experimental

    AZD0947 is a K+ channel opener, which was under investigation by AstraZeneca for the treatment of overactive bladder. … As of March 2003, the drug was in phase II trials; however, as of October 2004, it no longer appeared on the company’s development pipeline.

  10. Drug

    Nitisinone

    go.drugbank.com/drugs/DB00348
    Approved

    Nitisinone is a synthetic reversible inhibitor of 4-hydroxyphenylpyruvate dioxygenase. It is used in the treatment of hereditary tyrosinemia type 1 and Alkaptonuria. It is sold under the brand names Orfadin and Harliku.